Amplification of the MET oncogene is associated with poor prognosis, metastatic dissemination, and drug resistance in many malignancies. We developed a method to capture and characterize circulating tumor cells (CTCs) expressing c-MET using a ferromagnetic antibody. Immunofluorescence was used to characterize cells for c-MET, DAPI, and pan-CK, excluding CD45+ leukocytes. The assay was validated using appropriate cell line controls spiked into peripheral blood collected from healthy volunteers (HVs). In addition, peripheral blood was analyzed from patients (pts) with metastatic: gastric, pancreatic, colorectal, bladder, renal, or prostate cancers. CTCs captured by c-MET were enumerated, and DNA FISH for MET amplification was performed. The approach was highly sensitive (80%) for Implications: This study developed a novel c-MET CTC assay for detecting c-MET CTCs in patients with MET amplification and warrants further investigation to determine its clinical applicability.
renal cell, bladder, colorectal, gastric, and pancreatic cancers 26 . To date, therapies directed against c-MET have been unsuccessful in unselected patients or in patients selected based on tumor protein overexpression [31] [32] [33] . However, there are promising response rates for c-MET directed inhibitors in MET amplified gastric cancer 34, 35 and non-small cell lung cancer 36 , thus necessitating the development of a predictive biomarker to target c-MET.
Circulating tumor cells (CTCs) represent cells which are shed from either primary or metastatic sites, and which migrate in the circulation in the process of tumor metastasis. The measurement of CTCs in the peripheral bloodstream represents one avenue to develop tumorspecific biomarkers with both prognostic and predictive utility [37] [38] [39] .
The process of epithelial-mesenchymal transition (EMT) in malignant cells has been demonstrated in a variety of solid tumors and is an important part of metastasis 40 . Cells change from an epithelial phenotype, with tight adhesions and polarized layers, to a mesenchymal phenotype, without polarization. Cells can toggle between epithelial and mesenchymal phenotypes via transitions in what has been termed epithelial plasticity (EP); this important mechanism has been proposed to play an important role in tumorigenesis 41 . Several translational studies have suggested a link between loss of epithelial markers, gain of mesenchymal markers, and the induction of signaling pathways that promote survival and cellular proliferation [42] [43] [44] .
These transitions between epithelial and mesenchymal phenotypes are also fluid; our group previously found that the majority of CTCs from patients with metastatic prostate cancer and breast cancer co-express both epithelial (EpCAM, E-cadherin, and cytokeratins (CK)) and mesenchymal (vimentin, N-cadherin, and OB-cadherin) markers 45 . These methods have also previously been used to detect mesenchymal CTCs 46 hybridization (ISH) 47 . These studies and others suggest the existence of non-epithelial CTCs that have gained expression of mesenchymal markers and lost expression of epithelial markers 45, [47] [48] [49] [50] .
Although c-MET has not been a canonical marker of EP or the mesenchymal phenotype, c-MET signaling is essential for the migration of myogenic stem cells into limb buds of embryos 51 .
Therefore, c-MET has a physiologic role for mesenchymal cells, and, as noted above, is overexpressed in metastatic disease.
Therefore, given the importance of c-MET in the process of metastasis, EP, and treatment resistance, we hypothesized that CTCs may overexpress c-MET during the process of metastasis and that these CTCs may be captured and represent distinct CTC phenotypes from standard EpCAM-captured CTCs 45, [48] [49] [50] . The goals of this current study were to develop a c-MET CTC assay and to perform a pilot study to capture and characterize the prevalence of c-MET expressing CTCs in patients with metastatic gastrointestinal and genitourinary cancers.
Materials and Methods:

Development of novel c-MET CTC assay
We used the CellSearch ® assay for the traditional EpCAM CTC capture, as previously 
Specimen characteristics:
All cell lines were obtained through the Duke Cell Culture Facility and passaged in the GarciaBlanco laboratory for less than 6 months after attainment. Cell lines were grown to confluence in either cancer cell line) were used for assay characterization. The assay was tested for sensitivity and specificity using these cell lines spiked in buffer, as well as spiked into whole blood from healthy volunteers recruited at Duke University Medical Center through an IRB-approved protocol and after informed consent. Cells were counted and diluted, and between 30 and 10,000 cells were spiked in each sample tested. Since the CellSearch EpCAM CTC assay has been fully characterized, the cell lines A549, SiHA, and PC3 were only tested once. Once the HeLa cell line was found to be fully c-MET positive and EpCAM negative, the BT549 cell line was also tested only once in the c-MET CTC assay.
Immunofluorescence and flow cytometry:
Cells were harvested with cell dissociation buffer and fixed with 1% PFA. Cells were washed with PBS and then permeabilized with 0.1% triton in PBS for 30minutes at room temperature, then blocked with 10% goat-serum in PBS. For staining we adjusted the cell density to 1x10 the c-MET CTC assay but not the EpCAM CTC assay since the EpCAM CTC assay is fully validated in previous studies 53 .
All study subjects signed informed consent to participate in this Duke IRB approved, single institution, investigator initiated study. A single peripheral blood draw was performed. Subjects had peripheral whole blood collected into four 10mL Cellsave ® vacutainers. Samples were stored at ambient room temperature and processed within 48 hours of collection. 7.5mL of whole blood was run per sample, and duplicate samples were processed for c-MET and EpCAM capture.
CTC enumeration for c-MET and EpCAM capture was performed as described above. When c-MET CTCs were present, DNA fluorescent in situ hybridization (FISH) was performed using a dual color FISH probe for c-MET and SE7. A repeat free FISH probe for c-MET was prepared using BAC clones RP11-114O6 and CTD-2369N14 and labeled with PlatinumBright 550 (Leica Biosystems) as previously described 54 . The chromosome 7 centromere probe (SE7) was labeled with Platinum Bright 415 and was obtained from Leica Biosystems. Methods for performing FISH on CTC have been previously described 55 .
Statistical analysis
Descriptive statistics were used to describe clinical parameters and CTC enumeration for c-MET and EpCAM capture. Prevalence of detectable CTCs using c-MET capture was calculated as the proportion of patients with at least one c-MET CTC that was validated by replicate. The Wilcoxon ranksum test was used to assess the difference in the number of c-MET+/CD45+/CK+ cells among cancer patients and healthy controls. adenocarcinoma (10 pts), urothelial carcinoma (8 pts), gastro-esophageal adenocarcinoma (7 pts), and pancreatic adenocarcinoma (7 pts). Efforts were made to enroll patients with resistant disease to VEGF (RCC) or EGFR (colon) inhibitors, or for men with bone metastatic CRPC (prostate) in order to enrich for c-MET expression 13, 14, 20 . All patients had metastatic disease with predominantly lymph node, liver, lung, and bone metastases ( Table 1) . Most of the patients had undergone multiple lines of targeted and systemic chemotherapies. All of the prostate patients had received either combined androgen blockade or surgical castration, 9 had received either abiraterone or enzalutamide, 9 had received docetaxel, and all had bone metastases. Nine of the RCC patients (7 clear cell, 2 papillary and 1 collecting duct) were refractory to VEGF-targeting therapies including sunitinib, axitinib, and pazopanib. All 8 of the bladder cancer patients were refractory to previous platinum-based chemotherapy. Of the 7 gastro-esophageal cancer patients who were enrolled, 6 had received prior 5-FU//leucovorin (LV)/oxaliplatin, and 2 had received prior trastuzumab for HER2-positive disease. All of the colorectal cancer patients had been treated with 5-FU/LV/oxaliplatin, 9 had been treated with bevacizumab, and 6 had received prior EGFR targeting therapy (either cetuximab or panitumumab). Of the 7 pancreatic cancer patients, 6 had received prior 5-FU, 5 had received prior gemcitabine, 4 had received prior oxaliplatin, and 2 had received prior nab-paclitaxel. Further details are provided in Table 1. c-MET cells captured from four patients across four disease types c-MET CTCs and EpCAM CTCs were enumerated in duplicate in all patients and summarized ( Table 2) . c-MET CTCs meeting the criteria described above ( Figure 1A) were found in 4 patients 
(8%), and at least one EpCAM CTC was identified in 23 patients (44%) (Figure 2) . Of the 4 cases that had detectable c-MET CTCs, 3 cases were validated in replicate samples with MET amplification and trisomy 7 confirmed by DNA FISH, for a total cross-sectional prevalence of 6% (95% CI 1-16%). The subgroup cross-section point-estimated prevalence was 14% for gastric cancer, 10% for colorectal and RCC, and 13% for urothelial carcinoma. These cases are further described below in order to provide greater clinical context for the successful c-MET CTC capture events in this study. MET gene (representative shown in Figure 4D) . These results suggest a malignant origin to the c-MET captured CTCs.
c-MET+, CD45+, CK+ cells isolated from a subset of patients
During isolation of c-MET CTCs, we also isolated and identified rare cells, which were positive for both CD45 and pan-cytokeratin, and which had a nuclear morphology consistent with benign cells. 
Discussion
In this study, we have developed a novel, highly specific and minimally invasive assay for c- 
